Cargando…
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate pathogenic mechanisms, however, the five-drug chemoimmun...
Autores principales: | Amin, Amit Dipak, Peters, Tara L., Li, Lingxiao, Rajan, Soumya Sundara, Choudhari, Ramesh, Puvvada, Soham D., Schatz, Jonathan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411687/ https://www.ncbi.nlm.nih.gov/pubmed/28487884 http://dx.doi.org/10.1101/mcs.a001719 |
Ejemplares similares
-
The Mechanism of Cancer Drug Addiction in ALK-Positive T-Cell Lymphoma
por: Rajan, Soumya S., et al.
Publicado: (2019) -
Kinase overexpressing cancers responsive to drug withdrawal
por: Amin, Amit Dipak, et al.
Publicado: (2015) -
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447
por: Peters, Tara L., et al.
Publicado: (2016) -
A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature
por: Taverna, Josephine, et al.
Publicado: (2014) -
TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
por: Amin, Amit Dipak, et al.
Publicado: (2016)